Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Consensus "Moderate Buy": Eight brokerages cover Enanta (7 buys, 1 sell) with an average 12‑month price target of about $20.29.
• Recent quarter beat estimates—EPS of ($0.42) vs. ($0.54) expected and revenue $18.62M vs. $16.14M—yet the company remains unprofitable (negative PE and net margin) and analysts forecast ~($1.98) EPS for the year.
• Shares trade around $13.2895% of the stock and several funds (Janus Henderson, Krensavage, Farallon, Millennium) recently added large positions.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $20.2857.

Several analysts have issued reports on ENTA shares. Rodman & Renshaw initiated coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, March 26th. They set a "buy" rating and a $20.00 price target on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a report on Monday, April 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th.

Enanta Pharmaceuticals Stock Performance

ENTA opened at $13.28 on Tuesday. The business's 50-day simple moving average is $13.55 and its 200 day simple moving average is $13.29. Enanta Pharmaceuticals has a 52-week low of $4.96 and a 52-week high of $17.15. The firm has a market capitalization of $385.39 million, a PE ratio of -4.15 and a beta of 0.99.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.12. The firm had revenue of $18.62 million for the quarter, compared to analyst estimates of $16.14 million. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%. On average, research analysts forecast that Enanta Pharmaceuticals will post -1.98 earnings per share for the current year.

Institutional Trading of Enanta Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC increased its holdings in shares of Enanta Pharmaceuticals by 91.6% during the 4th quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company's stock worth $58,761,000 after acquiring an additional 1,782,745 shares during the last quarter. Commodore Capital LP bought a new position in Enanta Pharmaceuticals during the third quarter worth $9,576,000. Krensavage Asset Management LLC boosted its position in Enanta Pharmaceuticals by 30.8% during the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company's stock worth $43,626,000 after purchasing an additional 651,946 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 30.6% in the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company's stock valued at $43,719,000 after purchasing an additional 650,000 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company's stock valued at $7,435,000 after purchasing an additional 449,945 shares during the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.